Level Four Advisory Services’s Alexion Pharmaceuticals ALXN Stock Holding History

Level Four Advisory Services’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,064	Closed	-$1.67M	–	676
2021 Q2	$1.67M	Buy	9,064 +585	+7%	+$100K	0.12%	197
2021 Q1	$1.3M	Buy	8,479 +986	+13%	+$153K	0.1%	220
2020 Q4	$1.17M	Sell	7,493 -289	-4%	-$37.1K	0.09%	215
2020 Q3	$890K	Sell	7,782 -231	-3%	-$24.9K	0.07%	261
2020 Q2	$894K	Sell	8,013 -444	-5%	-$47.1K	0.07%	269
2020 Q1	$762K	Buy	8,457 +877	+12%	+$86.1K	0.09%	247
2019 Q4	$3.93M	Buy	7,580 +1,635	+28%	+$175K	0.16%	162
2019 Q3	$582K	Buy	5,945 +417	+8%	+$47K	0.06%	299
2019 Q2	$723K	Buy	5,528 +41	+0.7%	+$5.28K	0.07%	256
2019 Q1	$743K	Buy	5,487 +96	+2%	+$11.9K	0.08%	240
2018 Q4	$525K	Sell	5,391 -13	-0.2%	-$1.54K	0.07%	284
2018 Q3	$751K	Sell	5,404 -1,086	-17%	-$136K	0.08%	254
2018 Q2	$806K	Sell	6,490 -455	-7%	-$53.2K	0.06%	282
2018 Q1	$774K	Buy	6,945 +432	+7%	+$51.6K	0.06%	278
2017 Q4	$779K	Sell	6,513 -77	-1%	-$9.38K	0.06%	286
2017 Q3	$925K	Buy	6,590 +2,832	+75%	+$385K	0.08%	234
2017 Q2	$437K	Sell	3,758 -2,784	-43%	-$324K	0.07%	283
2017 Q1	$774K	Buy	6,542 +417	+7%	+$53.8K	0.08%	250
2016 Q4	$749K	Buy	+6,125	New	+$749K	0.1%	208

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Level Four Advisory Services's ALXN Position: Q3 2021 in Review

Level Four Advisory Services sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,064 shares — an estimated $1.67M sold.

Level Four Advisory Services first reported a position in ALXN in Q4 2016 and held it in 19 quarters. The position peaked at $3.93M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Level Four Advisory Services reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Level Four Advisory Services sold 9,064 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.67M.
Level Four Advisory Services first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 19 quarters.
Level Four Advisory Services's Alexion Pharmaceuticals position peaked at $3.93M in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Level Four Advisory Services's 13F filing for Q3 2021, filed 12 Oct 2021.